Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call
April 18 2019 - 4:05PM
Business Wire
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it
will host its first quarter 2019 investor update conference call
and webcast at 8:30 a.m. Eastern Time on Thursday, May 2, 2019.
Individuals interested in participating in the call should dial
(866) 393-4306 (U.S. and Canada) or (734) 385-2616 (international)
using conference ID number 8429338. To access the webcast, please
visit the Investors section of Ironwood’s website at
www.ironwoodpharma.com at least 15 minutes prior to the start of
the call to ensure adequate time for any software downloads that
may be required.
The call will be available for replay via telephone starting May
2, 2019 at approximately 11:30 a.m. Eastern Time, running through
11:59 p.m. Eastern Time on May 16, 2019. To listen to the replay,
dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406
(international) using conference ID number 8429338. The archived
webcast will be available on Ironwood’s website for 14 days
beginning approximately one hour after the call has completed.
About Ironwood PharmaceuticalsIronwood Pharmaceuticals
(Nasdaq: IRWD) is a GI-focused healthcare company focused on
creating medicines that make a difference for patients living with
GI diseases. We discovered, developed and are commercializing
linaclotide, the U.S. branded prescription market leader for adults
with irritable bowel syndrome with constipation (IBS-C) or chronic
idiopathic constipation (CIC). We are currently advancing a Phase
IIIb trial evaluating the efficacy and safety of linaclotide on
multiple abdominal symptoms, including bloating, pain, and
discomfort, in adult patients with IBS-C.
We are also advancing two late-stage, first-in-category GI
product candidates: IW-3718 is a gastric retentive formulation of a
bile acid sequestrant being developed for the potential treatment
of persistent gastroesophageal reflux disease, and MD-7246 is a
delayed-release formulation of linaclotide that is being evaluated
as an oral, intestinal, non-opioid, pain-relieving agent for
patients suffering from abdominal pain associated with IBS with
diarrhea.
Ironwood was founded in 1998 and is headquartered in Cambridge,
Mass. For more information, please visit our newly launched website
at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma;
information that may be important to investors will be routinely
posted in both these locations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190418005615/en/
Media and Investors:Meredith Kaya, 617-374-5082Vice
President, Investor Relations and Corporate
Communicationsmkaya@ironwoodpharma.com
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Sep 2023 to Sep 2024